Traceability in Artificial Intelligence: A Critical Look at Platforms in Dermatology
Although novel artificial intelligence-powered diagnostic applications are readily available to the public, how much can clinicians trust these tools?
Related Articles
Tandem CD20-CD19-Directed CAR T-Cell Therapy for Relapsed/Refractory DLBCL: Zamtocabtagene Autoleucel
Nirav Shah, MD, discusses findings from an interim analysis of the phase 2 DALY II trial, which is the first pivotal trial evaluating tandem CD20-CD19…
Top 5 Articles of the Week: January 26-31
Explore the top headlines of the week including innovation in scalp treatment, therapeutic updates in rosacea, and acne vulgaris insights from James Del Rosso, DO.
Combination of Baricitinib and Phototherapy in Adults With Active Vitiligo
This randomized clinical trial assesses the efficacy and adverse events of baricitinib combined with narrowband UV-B in adults with severe, active, nonsegmental vitiligo.
The Weekly Roundup: January 27–31
In case you missed it, this week we had news about awareness resources from the Skin Cancer Foundation, burn care disparities in skin of color,…
Review Finds HA Fillers Improve Skin Radiance
The meta-analysis found that HA fillers enhance skin hydration and glow, but do not significantly impact elasticity.
Western Atrial Fibrillation Symposium 2025: What to Expect, and Future Perspectives in Electrophysiology
In this episode, EP Lab Digest features a discussion with Bradley Knight, MD, and Nassir Marrouche, MD, about the upcoming Western Atrial Fibrillation Symposium, taking place February…
Real-World Data Supports Dupilumab for Prurigo Nodularis Treatment in China
85% of Chinese PN patients saw a PP-NRS improvement of ≥ 4 points after 12 weeks of treatment.
JCAD Podcast – JCAD TV
JCAD October 2024 Issue Highlights Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in…
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years
This nonrandomized clinical trial evaluates the long-term safety and efficacy of continuous treatment with deucravacitinib through 3 years in the POETYK PSO-1, PSO-2, and long-term…